Presentation Annual Results 2025

SKAN Group AG

Presentation of the 2025 Financial Results

24 March 2026

SKAN

Agenda

1. Overview of Business Year Burim Maraj (CFO)

2. Strategy execution

3. Financial Results 2025

4. First view of new CEO

5. Outlook

6. Questions and discussions

Jonas Greutert (CEO) Burim Maraj (CFO) Jonas Greutert (CEO) Jonas Greutert (CEO)

24 March 2026 SKAN Group AG Presentation of the 2025 Financial Results 3

SKAN

Overview of the 2025 financial year

Order Intake

in CHF million

370.6

+3.1%(1)

EBITDA

in CHF million

38.6

-32.3%(1)

Investments

in CHF million

45.9

-14.7%(1)

Net Sales

in CHF million

333.3

-7.7%(1)

EBITDA-Margin

as % of Net Sales

11.6

-4.2pp(1, 2)

Order Backlog

in CHF million

346.1

+8.7%(1)

Strong order intake from European customers, while orders from the

US were more hesitant; success rate for quotations around 50%.

Order backlog provides good visibility in the equipment business.

Net sales declined as a result of an exceptional number of project postponements, which shifted the corresponding sales and profits to the current year.

As a consequence, also EBITDA and EBITDA-Margin were below

previous year's level.Profit for 2025 amounted to CHF 17.6 million. The Board of Directors will propose a dividend of CHF 0.22 per share (payout ratio 30%).

Investments mainly used to build-up Pre-Approved Services.

Two strategic acquisitions to further broaden our offering to

customers.

24 March 2026 SKAN Group AG Presentation of the 2025 Financial Results

1. Changes compared to previous year 4

2. Percentage points

SKAN

Contrasting segment performance

Equipment & Solutions

Good orders for complex filling lines for oncology applications and biotechnologically produced injectable large molecules.

Weaker financial performance due to project postponements.

Gaps in production were filled with pre-production of standard isolators

(e.g. for quality control), which partially compensated for the shift of sales.

Good progress with Integrated Process Solutions; significant portion of R&D expenditures (7.4% of net sales) was allocated to this strategic initiative.

Services & Consumables

Segment performed well and installed base continued to expand.

Acquisitions of Metronik and ABC Transfer contributed to growth and earnings; support SKAN's strategy of increasing the share of services and consumables in total sales, thereby improving the Group's margin profile. Development of Pre-Approved Services successfully continued; initial customer feedback very positive; commercial launch planned for 2HY 2026.

SKAN

Agenda

1. Overview of Business Year Burim Maraj (CFO)

2. Strategy execution Jonas Greutert (CFO)

3. Financial Results 2025

4. First view of new CEO

5. Outlook

6. Questions and discussions

Burim Maraj (CFO) Jonas Greutert (CEO) Jonas Greutert (CEO)

SKAN

SKAN Group's growth strategy

Objectives

Accelerate digital

transformation

4

Accelerate growth in

services & consumables

3

2

Continue growth track-record Increase recurring revenue base Strengthen profitability

1

Fortify market leadership Expand addressable market

• Continuous innovation to meet customer's demand and to maintain technology leadership

• Continuous active contribution to new guidelines & regulations

• Investment in production capacity expansion and scale-up

• Continue joint developments with

  established fill-finish partners

• In-house development of Integrated Process Solutions combining automated robotics with isolator technology

• Expand offering to include software and digital integration services

• Increase global product lifecycle support with expanding installed base of isolators

• Further development of innovative consumables (e.g. closed vials, transfer systems, filling kits, betabags)

• Additional service offerings of Pre-approved Services to help customers shorten time-to-market

• Develop "One button release" paperless GMP compliant documentation

• Increase augmented virtual reality design support

• Leverage Artificial Intelligence for service efficiency

  
  
  

  SKAN

  Achievements and measures in 2025

  Objectives

  Accelerate digital

  transformation

  4

  Accelerate growth in

  services & consumables

  3

  2

  Continue growth track-record Increase recurring revenue base Strengthen profitability

  1

  Fortify market leadership Expand addressable market

• Approx. 50 eBeam systems successfully installed at customers (surface sterilization of RTU tubs containing pre-sterilized components,

  e.g. syringes, vials, or cartridges).

• Development of fully modular isolator specifically for highly flexible, fully aseptic ATMP manufacturing.

• New Integrated Process Solutions system based on latest robotics platform delivered by end of 2025.

• Acquisition of Metronik enhances our portfolio with automation and digitalization solutions for life-science manufacturing

• Acquisition of ABC Transfer expands our consumables portfolio.

• 8 in AT closed vials filled drugs are on the market and received 19 approvals by 6 major health authorities.

• First promising trials in deploying Artificial Intelligence knowledge management to drive service efficiency.

3

Accelerate growth in

services & consumables

Pre-Approved services launch planned in H2/2026

Key data Equipment

At start: filling equipment with potential to expand

At full capacity: a wide range of products can be

handled

Commercial use

H2/2026E: Planned start of commercial use with successive increase in capacity utilization over several years until full capacity is reached

With Pre-Approved Services, SKAN will offer customers the possibility to carry out their stability tests on our systems. This will allow our customers to shorten the time-to-market for a new drug significantly.

Significant investments were made by SKAN to develop pre-

approved services.

Start realization All equipment

of infrastructure brought in, start of and cleanroom installation

Concept

approved

Start interior

fitting

Validation Regulatory

completed, start approval approval process

Start of

commercial use

Q1/2023

Q3/2023

Q1/2024

Q3/2024

Q1/2026

H2/2026E

H2/2026E increase capacity utilization

Milestones

SKAN seeks intends-commercial production in H2 2026.

4

Accelerate digital

transformation

3

Accelerate growth in

services & consumables

SKAN and Metronik offer customers a holistic solution along the pharmaceutical value chain

Metronik is a leading provider of digitalization

and automation systems and solutions.Metronik's modular, web-based software serves as digital backbone of pharma production and meets the highest GMP requirements.

Focus on the regulated life sciences sector

with blue chip clients like Novartis, Sandoz, Stada.

More than 20 projects across ten European countries completed in 2025.

The combination of SKAN's aseptic expertise and Metronik's digital process integration creates added value for customers.

SKAN and Metronik share an entrepreneurial culture with uncompromising customer focus.

Founded in 1990 and headquartered in Ljubljana, Slovenia, Metronik employs over 160 highly qualified people and serves over 100 customers.

3

Accelerate growth in

services & consumables

Transfer bags from ABC Transfer expand SKAN's

portfolio of consumables

01

Alpha stainless steel door

Assembly on isolators

Receive beta containers or betabags

ABC Transfer is a leading innovator in patented secure rapid transfer systems, enhancing efficiency in pharmaceutical production.

Offers several types of registered products:

1. sterile transfer ports

   02

   Betacleancontainer

   Connects to Alpha doors.

   Ensures sterility and containment for

   the passage of tools.

   
   
   

2. sterile containers and

3. sterile transfer bags

The products are compatible with existing market solutions and meeting Annex 1 requirements.

Wide network of blue chip clients such as

03

Betacleanbag

Connects to doors

Ensures the passage of components or active ingredients.

GSK, Sanofi, Lilly and Merck.

Entrepreneurial culture with uncompromising customer focus.

Founded in 2019 and headquartered in Tours, France, ABC Transfer employs 11 highly qualified people and serves over 75 customers.

SKAN

Agenda

1. Overview of Business Year

2. Strategy execution

Burim Maraj (CFO) Jonas Greutert (CEO)

3. Financial Results 2025 Burim Maraj (CFO)

4. First view of new CEO

5. Outlook

6. Questions and discussions

Jonas Greutert (CEO) Jonas Greutert (CEO)

SKAN

Order intake momentum supports future growth

Order intake

+20.2%

213.0

-13.5%

177.2

182.3

157.7

1HY24 1HY25 2HY24 2HY25

(CHFm and ∆ in %)

Order intake by regions

(CHFm and ∆ in %) (1)

Comments

1.0x

1.1x

Order intake remains robust (+3.1% y-o-y), with resilient demand and solid order

+3.1%

359.5

370.6

2024 2025

Book-to-bill-ratio

+11.5%

230.8

207.0

+8.0%

62.4%

57.6%

97.9

105.8

-34.2%

27.2%

28.5%

48.1

31.6

-62.5%

13.4%

8.5%

6.4

1.8%

2.4

0.6%

Europe

2024 2025

Americas

Asia

Others

momentum supporting future net sales growth.

Pipeline largely consisting of oncology-related projects (e.g. Antibody Drug Conjugates).

Softer H2 order intake mainly driven by the U.S. market, where extended customer decision cycles delayed awards.

Book-to-bill-ratio improved from 1.0x to 1.1x, mainly reflecting the lower net sales level in the period while confirming continued healthy order intake.

Europe (62.4%) remained the core market, while the Americas share (28.5%) reflected more cautious customer decisions; U.S. growth was primarily driven by Services & Consumables.

Asia's share declined y-o-y against a strong

prior-year base.

SKAN

Net sales impacted by exceptional project postponements

Net sales

(CHFm and ∆ in %)

Order backlog

(CHFm and ∆ in %)

Comments

+8.7%

346.1

(1)

318.3

15-20

-7.7%

361.3

333.3

~48% strong net sales in

2nd half of the year

+47.7%

197.6 198.8

163.7

134.6

Net sales declined by 7.7% y-o-y, or 6.4% on a CER-adjusted basis, mainly reflecting an exceptionally high level of project postponements.

H2 net sales rose by ~48%, primarily driven by a catch-up effect from the sale of pre-produced standard systems (e.g. sterility testing).

The order backlog rose from CHF 318.3m to CHF 346.1m during the reporting year, which gives good planning visibility.

Approx. CHF 15m to 20m of the order backlog is subject to potential cancellation risk, with no impact on current-year net sales expectations as these orders are not included in the plan.

2024 2025

2024

2025

SKAN

EBITDA impacted by lower sales, with a markedly stronger H2 earnings contribution

Expenses

(CHFm and in % of net sales)

44.5

164.5

95.4

76.7

167.4

50.6

2024 2025

EBITDA

(CHFm and margin in %)

-32.3%

57.0

38.6

2024 2025

Comments

EBITDA generated

primarily in 2nd half of the year

37.7

0.9

1HY25

2HY25

EBITDA declined by 32.3% to CHF 38.6m, with margin at 11.6%, mainly due to lower net sales in project business and higher operating expenses.

EBITDA was generated almost exclusively in H2, reflecting a materially stronger second-half earnings profile, with an H2 EBITDA margin of around 19%.

Material intensity decreased from 26.4% to 23.0%, driven by a higher share of Services & Consumables, which also supported a slight improvement in gross margin.

Workforce increased by 284 employees to 1'755, including 208 from acquisitions and 76 organic additions, leading to a moderate rise in personnel expenses (+1.8%) and personnel intensity to 50.2%.

Other operating expenses rose by CHF 6.1m, driven by acquisitions, higher travel, and IT-

Material and external services Personnel expenses

Other operating expenses as % of net sales

related costs.

SKAN

Segment Equipment & Solutions (E&S)

Order intake / Backlog

(CHFm and ∆ in %)

2024 2025

+3.6%

Net sales

(CHFm and as of % of Group net sales)

75.0% 65.1%

EBITDA

(CHFm and margin in %)

11.2% 4.3%

Comments

Order intake reached CHF 248.5m (-2.6% YoY), impacted by delayed customer decisions, particularly in the US.

-2.6%

283.0

255.0

248.5

293.1

Order intake Backlog

(1)

-20.0%

270.9

216.8

2024 2025

2024 2025

Several customers secured production slots and placed engineering orders, paving the way for larger follow-on orders.

-68.9%

30.3

9.4

Net sales declined 20.0% YoY to CHF 216.8m, representing 65% of Group total, mainly due to project postponements and temporary suspension of a major GLP-1 project.

Segment EBITDA declined 68.9% to CHF 9.4m (4.3% margin), while H2 profitability recovered strongly from a negative CHF -9.1m EBITDA in H1, partly supported by the sale of pre-produced standard systems.

Strong continued investment in

innovation, with 7.4% of net sales

Share of net sales in % of Group net sales EBITDA margin in %

mainly allocated to integrated process solutions and general R&D.

SKAN

Segment Services & Consumables (S&C)

Order intake

(CHFm and ∆ in %)

Net sales

(CHFm and as of % of Group net sales)

EBITDA

(CHFm and margin in %)

Comments

35.4

53.1

25.0% 34.9% 29.5% 25.0%

+9.5%

29.2

26.6

Organic order intake remained stable, while net sales increased by 11%, against a high comparative base in 2024 driven mainly by two factors:

extraordinary performance of Aseptic Technologies.

Large single orders of spare parts packages and multi-year maintenance contracts.

Installed base increased further, supporting sustainable growth in S&C.

Metronik and ABC Transfer supported both growth and earnings (consolidated from August 2025).

EBITDA rose 9.5% to CHF 29.2m,

with a margin of 25.0%

Order backlog increased to CHF

53.1m (+50%), further strengthening

+17.0%

122.2

+2.4%

104.5

107.0

+28.9%

116.5

100.3

90.4

+11.0%

2024 2025 Acquisitions 2025 Organic

2024 2025 Acquisitions 2025 Organic

2024 2025

visibility in S&C.

Order backlog (CHFm)

Share of net sales in % of Group net sales EBITDA margin in %

SKAN

Strong operating cash flow supported by solid order intake and disciplined working capital management

Cash flow

(CHFm)

(+75.2%)

34.8

-1.8

94.1

29.3

53.7

-130.9

Operating CF

CHF 64.1m

109.0

+40.4

Return on capital employed (1)

(CHFm and in %)

21.5%

19.7%

14.3% 15.8% 15.3%

11.2%

Comments

Operating cash flow increased by

37.3% to CHF 64.1m (PY: CHF

46.7m), mainly driven by downpayments reflecting solid order intake and disciplined net working capital management.

Opening Balance

OCF excl.

∆ NWC

∆ NWC

Investing CF Financing CF

Conversion diff.

Closing Balance

2019 2020 2021 2022

Average capital employed ROCE

2023

2024

10.3%

193.2

207.2

191.8

145.8

95.3

80.0

246.4

2025

Investing cash flow reflects our continued capacity expansion in pre-approved services, with CHF

45.9m invested in PPE, while the remaining outflow relates to the two acquisitions.

Financing cash flow of CHF 109m mainly reflects the two acquisitions, funded through a new RCF, while the related goodwill was recognized in equity.

ROCE declined to 10.3%, reflecting higher capital employed of CHF

246.4m and lower EBIT, with the dilution mainly attributable to growth investments.

SKAN

Solid financing structure supporting future growth

Balance sheet as of 31 Dec.

(CHFm)

Comments

Cash and

cash equivalents

384.5

+25.1% +25.1%

481.1

94.1

384.5

208.2

481.1

Other current liabilities(3)

SKAN Group posts a net debt position of CHF-37.4m as of 31st December 2025.

Net Debt / EBITDA ratio of 0.97x, underscoring a low leverage profile and ample headroom to finance future

Other current assets(1)

Non-current assets(2)

Assets 2024

53.7

169.8

161.0

Assets 2025

181.6

205.4

161.6

1.1

9.8

9.5

6.4

196.2

Liabilities and equity 2024

1.8

13.8

129.7

13.1

114.4

Liabilities and equity 2025

Current financial liabilities Other non-current liabilities(4)

Non-current financial liabilities

Minority interest

Equity attributable to shareholders of SKAN Group AG

growth.

Non-current financial liabilities increased from CHF 9.5m to CHF 129.7m, primarily reflecting the two acquisitions and the RCF financing raised to fund them.

Total equity amounted to CHF 127.6m, corresponding to an equity ratio of 26.5% (PY: CHF 202.6m; 52.7%)

The lower equity ratio mainly reflects offsetting of the goodwill from the two acquisitions.

24 March 2026 SKAN Group AG Presentation of the 2025 Financial Results

Note: Rounding differences may occur.

1. Includes trade receivables, other current receivables, inventories, work in progress and prepayments & accrued income. 19

2. Includes property, plant and equipment, financial assets, intangible assets and deferred tax assets.

3. Includes trade payables, advance payments from customers, other current liabilities, current provisions, and accrued liabilit ies & deferred income.

4. Includes other non-current liabilities, deferred tax liabilities and non-current provisions.

SKAN

Proposal Dividend: 30% payout ratio

Net profit (1)

(CHFm and ∆ in %)

+47.5%

38.8

+38.6%

26.3

+78.8%

19.0

16.3

10.6

-58.1%

Earnings per share

(CHF and ∆ in %)

+47.5%

1.73

+39.3%

1.17

0.84 0.84

0.72

-58.1%

Dividend per share

(CHF and ∆ in %)

+14.3%

0.40

+40.0%

0.35

0.24

+4.2%

0.25

0.22

-45.0%

Comments

Proposed dividend of CHF 0.22/share (2024: 0.40/share)

50% from capital contribution reserves ("KER")

50% from retained earnings

Distribution of CHF 4.9m (PY: CHF

9.0m)

Dividend payout ratio of 30% of 2025 profit attributable to shareholders of SKAN Group AG (PY: 23%).

2021 2022 2023 2024 2025

2021 2022 2023 2024 2025

2021 2022 2023 2024 2025

Note: Rounding differences may occur.

av

1

Lower net sales reflecting the project-based nature of the business

2 Top-line visibility supported by solid order intake and order backlog

3

EBITDA margin below guidance, but with a strong second-half

recovery and continued investment in R&D to support future growth

4

High-margin Services & Consumables business further

expanded through the new acquisitions

5

Solid return on capital despite significant growth investments

6

Strong balance sheet & financing structure providing full flexibility for

future growth

SKAN

2025 - At a glance

SKAN

Agenda

1. Overview of Business Year

2. Strategy execution

3. Financial Results 2025

Burim Maraj (CFO) Burim Maraj (CFO) Burim Maraj (CFO)

4. First view of new CEO Jonas Greutert (CEO)

5. Outlook

6. Questions and discussions

Jonas Greutert (CEO)

The CEO's first impressions after ~80 days

Leading position in a growth market driven by structural tailwinds.

Leading technology and unique capabilities that are almost impossible to copy.

Powerful corporate culture with passionate

and dedicated employees.

Exceptionally strong, long-term partnerships with customers and key partners.

Right strategy in place to continue growth path and expand profitability.

Accelerate growth in Service &

Consumables, including:

Lauching pre-approved services in H2/2026 and securing first customers.

Completing the integration of recent

acquisitions (Metronik & ABC Transfer).

Implementing targeted process improvements following years strong growth.

SKAN

Agenda

1. Overview of Business Year

2. Strategy execution

3. Financial Results 2025

4. First view of new CEO

Burim Maraj (CFO) Burim Maraj (CFO) Burim Maraj (CFO) Jonas Greutert (CEO)

5. Outlook Jonas Greutert (CEO)

6. Questions and discussions

SKAN

Strong market drivers and confident business outlook

Market development Business development

SKAN Group is focused on a market that is benefiting from structural growth. Main drivers are: The underlying growth of the global pharmaceutical

and biotech market;The reinforcing trend towards injectable drugs (three quarters of drugs in development are designed for injectable dosage form);

The replacement of traditional cleanrooms with safer and more sustainable isolator technology;

The reshoring of pharmaceutical production.

As a consequence, demand for SKAN's equipment, services and consumables will continue, as evidenced by the solid order backlog and well-filled order pipeline.

Based on the structural growth drivers and the solid order backlog, the Board of Directors and management are confident for the current year.

We expect a softer H1 vs. H2 due to project timing.

Momentum in the biotech market is improving, with solid project discussions underway. As a result, we expect shorter decision cycles and fewer investment delays than last year.

Cell & Gene Therapy is rebounding, with the market recovering after 2-3 years of capital scarcity. We expect to benefit from this renewed momentum going forward.

With our premium technology and the capabilities gained through the recent acquisitions, SKAN is well positioned to deliver a holistic offering along the pharmaceutical value chain, enhancing customer value and unlocking additional growth potential.

SKAN

Guidance and mid-term outlook

Metric 2026 Targets(1) Mid-Term targets

Group net sales growth

Upper teens

Mid- to upper teens

Segment net sales growth

(2)

E&S

S&C

E&S

S&C

EBITDA margin 13 - 15%

Gradually increase profitability level to upper teens in the mid-term. Potential for further increase beyond mid-term period.

24 March 2026 SKAN Group AG Presentation of the 2025 Financial Results

1. 2026 targets assume no further deterioration (direct or indirect) of economic general conditions and other unpredictable 26

   development of the geopolitical situation.

2. E&S refers to Equipment & Solutions. S&C refers to Services & Consumables.

SKAN

Agenda

1. Overview of Business Year

2. Strategy execution

3. Financial Results 2025

4. First view of new CEO

5. Outlook

Jonas Greutert (CEO) Jonas Greutert (CEO) Burim Maraj (CFO) Jonas Greutert (CEO) Jonas Greutert (CEO)

6. Questions and discussions

Together always one step ahead!

SKAN

Abbreviations and Definitions

Alternative Financial Performance Measures (APM)

EBITDA: Operating result (EBIT) plus depreciation, amortisation. EBITDA margin: EBITDA as a percentage of net sales from goods. EBT: Profit before income taxes.

Equity ratio: Equity at the end of the period divided by total assets at the end of the period.

Headcount: Number of people employed by SKAN Group at the time

indicated (i.e. excluding contractors).

Book-to-bill ratio: Order intake divided by net sales.

Net Cash: Cash and cash equivalents including liquid funds investment less current and non-current financial liabilities.

Net working capital (NWC): Total current assets (excluding cash and cash equivalents) minus trade payables, advance payments from customers, other current liabilities, current provisions and accrued liabilities and deferred income.

Operating result (EBIT): Earnings before total financial result and income taxes.

Return on capital employed (ROCE): Operating result (EBIT) divided by the sum of the average total assets minus the average current liabilities, expressed as a percentage.

Order intake: Total value of new customer orders received within the financial year, stated at order values. New orders or cancellations received after the balance sheet date are not included.

Order backlog: Total value of customer orders received but not yet fulfilled, stated at the respective order values. New orders or cancellations received after the balance sheet date are not included.